News | May 12, 2026
Plus Therapeutics subsidiary clears key Medicare milestone
Paves way for CNS cancer test rollout
Paves way for CNS cancer test rollout
Clinical guidelines and expert consensus recommend 1.2–1.5 g/kg/day protein intake during therapy to help preserve muscle mass
NEJM study shows strong protection across strains
The company highlights role of integrated genomics and multi-omics research at the Illumina Multiomics Summit India 2026 held in New Delhi and Bengaluru
The acquisition gives Bayer full rights to PER-001, an experimental therapy now in Phase II clinical trials for Glaucoma and Diabetic Retinopathy
The company says the product will now be distributed exclusively through Anovo Specialty Pharmacy
New policy aims to standardise screening, diagnosis and lifelong care for children with diabetes across India’s public health system
The Committee backed the combination based on results from the CAPItello-281 Phase III trial, marking a key milestone in the regulatory pathway for AstraZeneca’s targeted therapy strategy in prostate cancer
The renewal covers two versions of the IQOS device and three HEETS tobacco variants
While Drugs for Neglected Diseases initiative (DNDi) drives the R&D for neglected diseases, we collaborate with pharmaceutical companies at multiple stages, including sourcing promising molecules
Subscribe To Our Newsletter & Stay Updated
